EBITDA Margin (Annual)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

BioMarin Pharmaceutical Inc. (BMRN) had EBITDA Margin of 15.03% for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$3.22B
Net Income	$348.90M
Cost of Goods Sold	$717.44M
Gross Profit	$2.50B
Operating Expenses	$2.81B
Operating Income	$409.48M
Non-Operating Income/Expense	$73.00M
Pre-Tax Income	$482.48M
Normalized Pre-Tax Income	$482.48M
Income after Taxes	$348.90M
Income from Continuous Operations	$348.90M
Consolidated Net Income/Loss	$348.90M
Normalized Income after Taxes	$348.90M
EBIT	$409.48M
EBITDA	$484.23M
Weighted-Average Shares Outstanding (Basic)	191.79M
Weighted-Average Shares Outstanding (Diluted)	197.39M
Earnings per Share (EPS) (Basic)	$1.82
Earnings per Share (EPS) (Diluted)	$1.80
Balance Sheet Financials
Current Assets	$3.95B
Property, Plant, and Equipment	$952.51M
Long-Term Assets	$3.64B
Total Assets	$7.59B
Current Liabilities	$759.03M
Long-Term Debt	$597.18M
Long-Term Liabilities	$747.99M
Total Liabilities	$1.51B
Common Equity	$6.09B
Tangible Shareholders Equity	$5.68B
Shareholders Equity	$6.09B
Common Shares Outstanding	192.30M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$827.99M
Cash Flow from Investing Activities	$-414.24M
Cash Flow from Financial Activities	$-42.39M
Beginning Cash	$942.84M
End Cash	$1.31B
Increase/Decrease in Cash	$368.84M
Stock-Based Compensation	$181.41M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.21
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.09
Debt to Equity Ratio	0.10
Gross Margin	77.73%
Operating Margin	12.71%
EBIT Margin	12.71%
EBITDA Margin	15.03%
Pre-Tax Profit Margin	14.98%
Profit Margin	10.83%
Free Cash Flow	$724.96M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.42
Inventory Turnover	0.55
Receiveable Turnover	3.55
Days Sales in Receivables	102.91
Return on Equity	5.73%
Return on Tangible Equity	6.15%
Return on Assets	4.59%
Return on Investments	5.22%
Book Value Per Share	$31.65
Free Cash Flow per Share	$3.67
Operating Cash Flow per Share	$4.19

Data from Zacks Investment Research, Inc.